Primary hyperaldosteronism: diagnosis and treatment

Main Article Content

L.A. Nikitiuk
A.M. Kravchenko
V.S. Pasko
A.O. Kovalska


The aspects of primary hyperaldosteronism that have an important social and medical value are examined in this lecture. It is underlined that in some patients with timely diagnosis and choice of optimal therapeutic approach, a complete recovery is possible. In spite of improvement of laboratory and instrumental research methods, drug and surgical treatment, the problem of diagnosis and therapy of primary hyperaldosteronism is still of high relevance. The success of treatment and prognosis in these patients is directly dependent on the alertness of therapists, endocrinologists and cardiologists regarding symptomatic arterial hypertension, from the knowledge of the clinical picture, the tactics of the survey and the approaches to therapy.

Article Details

How to Cite
Nikitiuk, L., A. Kravchenko, V. Pasko, and A. Kovalska. “Primary Hyperaldosteronism: Diagnosis and Treatment”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 8, Dec. 2017, pp. 604-11, doi:10.22141/2224-0721.13.8.2017.119278.


Shchekaturova LV. Spectrum of Clinical and Pathogenetic Forms of Primary Hyperaldosteronism. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2015;2(66):132-137.

Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies – a review of the current literature. Horm Metab Res. 2012 Mar;44(3):157-62. doi: 10.1055/s-0031-1295438.

Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300. doi: 10.1016/j.jacc.2006.07.059.

Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of Plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005 Feb;51(2):386-94. doi: 10.1373/clinchem.2004.041780.

Hannemann A, Bidlingmaier M, Friedrich N, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol. 2012 Jul;167(1):7-15. doi: 10.1530/EJE-11-1013.

Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013 Jul;62(1):62-9. doi: 10.1161/HYPERTENSIONAHA.113.01316.

Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension. 2012 Sep;60(3):618-24. doi: 10.1161/HYPERTENSIONAHA.112.197111.

Lin YH, Lin LY, Chen A, et al. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis. 2012 Mar;221(1):154-9. doi: 10.1016/j.atherosclerosis.2011.12.003.

Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007 Nov;50(5):911-8. doi: 10.1161/HYPERTENSIONAHA.107.095448.

Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2010 Mar;95(3):1360-4. doi: 10.1210/jc.2009-1763.

Wu VC, Kuo CC, Wang SM, et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens. 2011 Sep;29(9):1778-86. doi: 10.1097/HJH.0b013e3283495cbb.

Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg. 2006 May;141(5):497-502; discussion 502-3. doi: 10.1001/archsurg.141.5.497.

Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg. 2005 Feb;29(2):155-9. doi: 10.1007/s00268-004-7496-z.

Vonend O, Ockenfels N, Gao X, et al. Adrenal venous sampling: evaluation of the German Conn’s registry. Hypertension. 2011 May;57(5):990-5. doi: 10.1161/HYPERTENSIONAHA.110.168484.

Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151–160. Hypertension. 2014 Jan;63(1):151-60. doi: 10.1161/HYPERTENSIONAHA.113.02097.

Webb R, Mathur A, Chang R, et al. What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol. 2012 Jun;19(6):1881-6. doi: 10.1245/s10434-011-2121-5.

Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf). 2009 Jan;70(1):14-7. doi: 10.1111/j.1365-2265.2008.03450.x.

Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab. 2011 Sep;96(9):2813-20. doi: 10.1210/jc.2011-0354.

Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension. 2008 Sep;52(3):529-34. doi: 10.1161/HYPERTENSIONAHA.108.114140.

Bernini G, Galetta F, Franzoni F, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens. 2008 Dec;26(12):2399-405. doi: 10.1097/HJH.0b013e32831286fd.

Holaj R, Zelinka T, Wichterle D, Petrák O, Strauch B, Widimský J Jr. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens. 2007 Jul;25(7):1451-7. doi: 10.1097/HJH.0b013e3281268532.

Tsuchiya K, Yoshimoto T, Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J. 2009;56(4):553-9. PMID: 19352049.

Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008 Jan 14;168(1):80-5. doi: 10.1001/archinternmed.2007.33.

Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008 May;51(5):1366-71. doi: 10.1161/HYPERTENSIONAHA.108.111369.

Strauch B, Petrák O, Zelinka T, et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens. 2008 Oct;21(10):1086-92. doi: 10.1038/ajh.2008.243.

Miyake Y, Tanaka K, Nishikawa T, et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J. 2014;61(1):35-40. PMID: 24077222.

Fischer E, Hanslik G, Pallauf A, et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab. 2012 Nov;97(11):3965-73. doi: 10.1210/jc.2012-2234.

Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011 May;29(5):980-90. doi: 10.1097/HJH.0b013e3283455ca5.

Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008 Mar;9(4):509-15. doi: 10.1517/14656566.9.4.509.

Iwakura Y, Morimoto R, Kudo M, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2014 May;99(5):1593-8. doi: 10.1210/jc.2013-2180.

Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am. 2011 Jun;40(2):333-41, viii. doi: 10.1016/j.ecl.2011.01.012.